Problem#3Mimicking nature by codelivery of stimulant and inhibitor

Of developmental biology this study was based on the

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: elopmental biology. This study was based on the hypothesis that clear demarcation of stimulatory zones for regeneration can be achieved via appropriate codelivery of stimulatory and inhibitory factors. This hypothesis was examined in the context of VEGF-driven angiogenesis, using delivery of both recombinant human VEGF and an angiogenic inhibitor, anti-VEGF antibody (anti-VEGF) (17), and utilizing a biodegradable polymer scaffold system to allow local and sustained release of the two factors. The ability of this approach to spatially regulate angiogenesis was examined in a model of hind-limb ischemia (18), due to its relevance to clinical situations requiring revascularization interventions. Materials and Methods Cell Culture and in Vitro Sprouting Assay. Dermal human vascular endothelial cells were seeded onto microcarrier beads and subsequently embedded in fibrin gels. Detailed protocols are included in SI Text. Gels were incubated at 37 °C for 30 min, and media of experimental conditions were placed on top of the gel. Experimental media were prepared by adding appropriate concentrations of VEGF and anti-VEGF to EGM-2MV without the growth factor supplements, but with the addition of 10 ng∕mL hepatocyte growth factor for all conditions. After 4 d, the gels were fixed with 4% paraformaldehyde. Subsequent to fixing, samples were stained with DAPI and visualized at 10× objective magnification with an Olympus IX2 microscope. Sprouts were identified as continuous multicellular structures extended from the microcarrier beads with a minimum of two cells in the structure. Scaffold Fabrication. An 85∶15, 120-kD copolymer of D,L-lactide and glycolide (PLG) (Alkermes) was used in a gas-foaming process to form macroporous PLG matrix scaffolds (19). All scaffolds were cylinders 4.2 mm in diameter and 3 mm in thickness. Detailed protocol for constructing scaffolds is included in SI Text. Four types of scaffolds were fabricated: (i) blank scaffolds without protein incorporation (B), (ii) scaffolds with 4 μg of VEGF (V), (iii) 3-layered scaffolds with a 1-mm central layer containing 4 μg of VEGF and two surrounding 1-mm layers without protein incorporation (BVB for Blank-VEGF-Blank), and (iv) three-layered scaffolds with a 1-mm central layer containing 4 μg of VEGF and two surrounding 1-mm layers each incorporating 20 μg of anti-VEGF (R&D Systems AB-293-NA) (AVA for anti-VEGF-VEGFanti-VEGF). Quantification of Protein Release Kinetics. The release kinetics of anti-VEGF and VEGF from each layer of the scaffold were determined using 0.11 μCi 125 I-labeled anti-mouse IgG (PerkinElmer) and 0.11 μCi 125 I-labeled human VEGF (PerkinElmer), respectively, as tracers. The tracers were entrapped in scaffolds using an identical process with the remaining bulk quantities consisting of unlabeled anti-VEGF and unlabeled VEGF, respectively. The total Author contributions: W.W.Y. designed research; W.W.Y., N.R.D., C.H.C., and E.A.S. performed research; W.W.Y. and...
View Full Document

This document was uploaded on 09/21/2013.

Ask a homework question - tutors are online